Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Silicon containing doai
Reexamination Certificate
2005-06-14
2005-06-14
Davis, Brian (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Silicon containing doai
C514S511000, C544S155000, C544S159000, C544S380000, C544S391000, C546S285000, C546S342000, C548S127000, C548S247000, C548S537000, C548S538000, C548S573000, C549S214000, C556S404000, C556S415000, C556S418000, C556S423000, C556S440000, C560S010000, C560S036000, C562S441000
Reexamination Certificate
active
06906046
ABSTRACT:
Benzobicyclooctane compounds, their use in inhibiting cellular events involving TNF-α and IL-8, and in the treatment of inflammation events in general; a combinatorial library of diverse bicyclooctanes and process for their synthesis as a library and as individual compounds.
REFERENCES:
patent: 3949987 (1976-04-01), Candor
patent: 4655451 (1987-04-01), Townsley
patent: 4666157 (1987-05-01), Bodine et al.
patent: 4698363 (1987-10-01), Hart
patent: 5403953 (1995-04-01), de Nanteuil et al.
patent: 5558333 (1996-09-01), Kelson et al.
patent: 5645499 (1997-07-01), Lewis
patent: 5674905 (1997-10-01), Kalindjian et al.
patent: 5710159 (1998-01-01), Voss et al.
patent: 5739163 (1998-04-01), Cain et al.
patent: 5779566 (1998-07-01), Wilens
patent: 5849736 (1998-12-01), Wityak et al.
patent: 5882269 (1999-03-01), Lewis
patent: 6147224 (2000-11-01), Vuligonda et al.
patent: 6211171 (2001-04-01), Sawynok et al.
Database CAPLUS on STN, Acc. No. 1970:414534, Takeda et al., Tetrahedron (1970), 26(6), p. 1435-51 (CAPLUS abstract).
Database CAPLUS on STN, Acc. No. 1970:414534,Takeda et al, Tetrahedron (1970), 26(6), p. 1435-51 (abstract).
Jackson, “A mild and selective method for the cleavage oftert-butyl esters,”Tetrahedron Letters 42(31):5163-5165, Jul. 30, 2001.
Hagishita et al., “Optical Activity by βΓ-Unsaturated Ketones. Part 1. Effect of the Direction of the Electric Tansition Dipole Moment in the Aromatic Group in Benzobicyclo[2.2.2]ocen-2-one t Derivatives,”Journal of the Chemical Society Perkin Transactions 2(14):1937-1941, 1977.
Karlsson et al., “Biosensor Analysis of Drug-Target Interactions: Direct and Competitive Binding Assays for Investigation of Interactions between Thrombin and Thrombin Inhibitors,”Anaylytical Biochemmistry 278:1-13, 2000.
Shimizu et al., “High-performance affinity beads for identifying drup receptors,”Nature Biotechnology 18(8):877-881, Aug. 2000.
Singh et al., “9,10-[1,4-Dihydrosubstituted-naphthalene-2-oxo-endo/exo-1,4-diyl]-N-arylsuccinimide : Congifurational Assignment by Pmr Spectroscopy,”Journal of the Indian Chemical Society 67:818-820, Oct. 1990.
Takeda et al., “Diels-Alder Reaction. IX. Reaction of the 1,7-, 2,7-, 2,6- and 1,6-dihydroxynaphthalene and 6-bromo-2-naphthol with maleic anhydride and the resolution of some derivatives of the adducts,”Tetrahedron 26:1435-1451, 1970.
Takeda et al., “Studies on Bis-quaternary Ammonium Salts of the Dibenzobicycol(2.2.2)octadienopyrrolidine Series. Part 1. Synthesis,”Shionogi Kenkyusho Nempo 15:53-59, 1965.
Van Broeck et al., “Smooth Generation of 3H-2-Benzopyran-3-ones and their Diesl-Alder Reactions with Olefinic Dienophiles,”Journal of the Chemical Society, Perkin Transactions 1 3:639-644, 1991.
Baughman Ted A.
Darwish Ihab
Howbert J. Jeffry
Jackson Randy W.
Celltech R & D Inc.
Davis Brian
Davis , Wright, Tremaine, LLP
Rotter Jane E.
LandOfFree
Pharmaceutical uses and synthesis of benzobicyclooctanes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical uses and synthesis of benzobicyclooctanes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical uses and synthesis of benzobicyclooctanes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3514585